Literature DB >> 11722592

Constitutive activation of STAT transcription factors in acute myelogenous leukemia.

K Spiekermann1, S Biethahn, S Wilde, W Hiddemann, F Alves.   

Abstract

Hematopoietic growth factors (HGF) are essential for proliferation and differentiation of hematopoietic precursors and activate a distinct set of JAK-STAT (Janus kinases-signal transducers and activators of transcription) proteins. Previous results from our group have shown a strong expression of JAK-STAT proteins in primary acute myelogenous leukemia (AML) blasts and AML cell lines. Here, we asked whether a constitutive activation of the JAK-STAT pathway might be involved in the pathogenesis of AML. We could demonstrate a constitutive activation of STAT1, 3 and 5 by immunoprecipitation of the tyrosine phosphorylated proteins in different human AML cell lines. Three patterns of STAT activation were found: (I) activation of only STAT1, (II) activation of STAT1 in combination with STAT3, and (III) activation of STAT1, 3 and 5. Furthermore, STAT1 and 3 formed stable heterodimers only in cell lines with constitutive STAT3 activation. In all cell lines analyzed, tyrosine phosphorylation of the four known Janus kinases could not be detected, although JAK1 was stably associated with STAT3. To further analyze whether a constitutive activation of tyrosine kinases might contribute to the autonomous growth of AML blasts, inhibitor studies were performed. The tyrphostin AG490, an inhibitor of the JAK-STAT pathway, but not A1, an inactive tyrphostin induced a time- and dose-dependent growth arrest without overt morphological signs of differentiation in AML cell lines. Our results show that STAT transcription factors are constitutively activated in human AML cell lines and might contribute to the autonomous proliferation of AML blasts. Inhibition of this pathway might be of interest for the establishment of more specific antileukemic strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11722592

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  31 in total

1.  Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.

Authors:  Anne Trécul; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2012-01-25       Impact factor: 5.523

2.  JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

Authors:  Thomas Mercher; Gerlinde Wernig; Sandra A Moore; Ross L Levine; Ting-Lei Gu; Stefan Fröhling; Dana Cullen; Roberto D Polakiewicz; Olivier A Bernard; Titus J Boggon; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

Review 3.  Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Authors:  Mustafa Benekli; Heinz Baumann; Meir Wetzler
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 4.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

5.  Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.

Authors:  Alireza Eghtedar; Srdan Verstovsek; Zeev Estrov; Jan Burger; Jorge Cortes; Carol Bivins; Stefan Faderl; Alessandra Ferrajoli; Gautam Borthakur; Solly George; Peggy A Scherle; Robert C Newton; Hagop M Kantarjian; Farhad Ravandi
Journal:  Blood       Date:  2012-03-15       Impact factor: 22.113

6.  Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Authors:  Zohar Sachs; Raha A Been; Krista J DeCoursin; Hanh T Nguyen; Nurul A Mohd Hassan; Klara E Noble-Orcutt; Craig E Eckfeldt; Emily J Pomeroy; Ernesto Diaz-Flores; Jennifer L Geurts; Miechaleen D Diers; Diane E Hasz; Kelly J Morgan; Margaret L MacMillan; Kevin M Shannon; David A Largaespada; Stephen M Wiesner
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

7.  Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor.

Authors:  Michele S Redell; Marcos J Ruiz; Todd A Alonzo; Robert B Gerbing; David J Tweardy
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

8.  FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report.

Authors:  Michele S Redell; Marcos J Ruiz; Robert B Gerbing; Todd A Alonzo; Beverly J Lange; David J Tweardy; Soheil Meshinchi
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

Review 9.  STAT3 as a target for inducing apoptosis in solid and hematological tumors.

Authors:  Khandaker Al Zaid Siddiquee; James Turkson
Journal:  Cell Res       Date:  2008-02       Impact factor: 25.617

10.  Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3.

Authors:  Nam-Hoon Kim; Mun-Yong Lee; Seon-Joo Park; Jeong-Sun Choi; Mi-Kyung Oh; In-Sook Kim
Journal:  Immunology       Date:  2007-07-20       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.